Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Mylan-Atazanavir · DIN 02456877 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2017-06-29 Health Canada: Marketed since 2017-05-03 · brand MYLAN-ATAZANAVIR · ATC J05AE08 ATAZANAVIR · form Capsule · route Oral · ingredients ATAZANAVIR (ATAZANAVIR SULFATE) 150 MG · company Mylan pharmaceuticals ulc · schedule Prescription

DIN 02456877: Mylan-Atazanavir Raw flags: sec3=Y Item: 081800080; group id 64; item number 0126; lccId None; manufacturer id MYL Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $2.8386; ministry $2.8386 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456877 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94389

Interchangeable products

Jamp Atazanavir · DIN 02513102 · $2.8386 Reyataz · DIN 02248610 · $2.8386 Teva-Atazanavir · DIN 02443791 · $2.8386

Shortage status: active shortage (reported 2021-09-07, last updated 2022-05-31) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456877

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Teva-Atazanavir · DIN 02443791 Manufacturer: Teva Canada Limited; listing date 2017-06-29 Health Canada: Marketed since 2017-04-18 · brand TEVA-ATAZANAVIR · ATC J05AE08 ATAZANAVIR · form Capsule · route Oral · ingredients ATAZANAVIR (ATAZANAVIR SULFATE) 150 MG · company Teva canada limited · schedule Prescription

DIN 02443791: Teva-Atazanavir Raw flags: sec3=Y Item: 081800080; group id 64; item number 0126; lccId None; manufacturer id TEV Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $2.8386; ministry $2.8386 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443791 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92854

Interchangeable products

Jamp Atazanavir · DIN 02513102 · $2.8386 Mylan-Atazanavir · DIN 02456877 · $2.8386 Reyataz · DIN 02248610 · $2.8386

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443791

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Mylan-Atazanavir · DIN 02456885 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2017-06-29 Health Canada: Marketed since 2017-05-03 · brand MYLAN-ATAZANAVIR · ATC J05AE08 ATAZANAVIR · form Capsule · route Oral · ingredients ATAZANAVIR (ATAZANAVIR SULFATE) 200 MG · company Mylan pharmaceuticals ulc · schedule Prescription

DIN 02456885: Mylan-Atazanavir Raw flags: sec3=Y Item: 081800081; group id 64; item number 0127; lccId None; manufacturer id MYL Source form: Cap; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $2.8552; ministry $2.8552 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456885 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94390

Interchangeable products

Jamp Atazanavir · DIN 02513110 · $2.8552 Reyataz · DIN 02248611 · $2.8552 Teva-Atazanavir · DIN 02443813 · $2.8552

Shortage status: active shortage (reported 2021-08-03, last updated 2022-05-31) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456885

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Teva-Atazanavir · DIN 02443813 Manufacturer: Teva Canada Limited; listing date 2017-06-29 Health Canada: Marketed since 2017-04-18 · brand TEVA-ATAZANAVIR · ATC J05AE08 ATAZANAVIR · form Capsule · route Oral · ingredients ATAZANAVIR (ATAZANAVIR SULFATE) 200 MG · company Teva canada limited · schedule Prescription

DIN 02443813: Teva-Atazanavir Raw flags: sec3=Y Item: 081800081; group id 64; item number 0127; lccId None; manufacturer id TEV Source form: Cap; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $2.8552; ministry $2.8552 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443813 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92856

Interchangeable products

Jamp Atazanavir · DIN 02513110 · $2.8552 Mylan-Atazanavir · DIN 02456885 · $2.8552 Reyataz · DIN 02248611 · $2.8552

Shortage status: resolved shortage (ended 2021-01-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443813

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Atazanavir · DIN 02456893 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2017-06-29 Health Canada: Marketed since 2017-05-02 · brand MYLAN-ATAZANAVIR · ATC J05AE08 ATAZANAVIR · form Capsule · route Oral · ingredients ATAZANAVIR (ATAZANAVIR SULFATE) 300 MG · company Mylan pharmaceuticals ulc · schedule Prescription

DIN 02456893: Mylan-Atazanavir Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 081800388; group id 64; item number 0128; lccId None; manufacturer id MYL Source form: Cap; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $19.0681; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456893 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94391

Interchangeable products

Jamp Atazanavir · DIN 02513129 · not recorded Reyataz · DIN 02294176 · not recorded Teva-Atazanavir · DIN 02443821 · not recorded

Shortage status: active shortage (reported 2021-08-03, last updated 2022-05-31) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456893

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Atazanavir · DIN 02443821 Manufacturer: Teva Canada Limited; listing date 2017-06-29 Health Canada: Marketed since 2017-04-18 · brand TEVA-ATAZANAVIR · ATC J05AE08 ATAZANAVIR · form Capsule · route Oral · ingredients ATAZANAVIR (ATAZANAVIR SULFATE) 300 MG · company Teva canada limited · schedule Prescription

DIN 02443821: Teva-Atazanavir Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 081800388; group id 64; item number 0128; lccId None; manufacturer id TEV Source form: Cap; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $19.0681; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443821 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92857

Interchangeable products

Jamp Atazanavir · DIN 02513129 · not recorded Mylan-Atazanavir · DIN 02456893 · not recorded Reyataz · DIN 02294176 · not recorded

Shortage status: resolved shortage (ended 2020-07-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443821

Shortage record checked 2026-09-13T08:10:21.292534+00:00